|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.59 / 1.70|
U.S. FORE-SIGHT cerebral oximetry sales up 18% for the quarter with record domestic monitor placements
Marks divestiture of final, non-core legacy assets and allows sole focus on FORE-SIGHT® tissue oximetry products
FORE-SIGHT Cerebral Oximetry Sales up 17% for the Full Year
FORE-SIGHT Cerebral Oximetry Sales Up 33% for the Quarter
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.